Titan Pharmaceuticals, Inc.
TTNP
$3.70
-$0.09-2.38%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | 0.00 | 4.00K | 87.00K | 185.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 0.00 | 4.00K | 87.00K | 185.00K |
| Cost of Revenue | -- | 487.00K | 911.00K | 1.35M | 1.91M |
| Gross Profit | -- | -487.00K | -907.00K | -1.27M | -1.73M |
| SG&A Expenses | 4.56M | 5.34M | 6.22M | 5.38M | 5.55M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.56M | 5.82M | 7.13M | 6.73M | 7.46M |
| Operating Income | -4.56M | -5.82M | -7.13M | -6.64M | -7.28M |
| Income Before Tax | -4.71M | -5.89M | -5.46M | -4.95M | -5.57M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.71 | -5.89 | -5.46 | -4.95 | -5.57 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.71M | -5.89M | -5.46M | -4.95M | -5.57M |
| EBIT | -4.56M | -5.82M | -7.13M | -6.64M | -7.28M |
| EBITDA | -4.55M | -5.81M | -7.09M | -6.57M | -7.17M |
| EPS Basic | -5.23 | -6.98 | -6.59 | -6.41 | -7.40 |
| Normalized Basic EPS | -3.27 | -4.38 | -5.58 | -5.47 | -6.09 |
| EPS Diluted | -5.23 | -6.98 | -6.59 | -6.41 | -7.40 |
| Normalized Diluted EPS | -3.27 | -4.38 | -5.58 | -5.47 | -6.09 |
| Average Basic Shares Outstanding | 3.60M | 3.44M | 3.27M | 3.11M | 3.01M |
| Average Diluted Shares Outstanding | 3.60M | 3.44M | 3.27M | 3.11M | 3.01M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |